Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + spartalizumab versus docetaxel in pretreated advanced non-small cell lung cancer
2018-001420-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Capmatinib + spartalizumab with Docetaxel (2 arms). Primary endpoint: Incidence and severity of adverse events and serious adverse events. Started Oct 2018; status: completed.
02
Drugs
capmatinibspartalizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001420-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001420-19.